Cargando…

Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance

BACKGROUND: Hepatitis B e antigen (HBeAg) seroclearance has been considered as the treatment endpoint in HBeAg-positive patients with chronic hepatitis B (CHB). Although HBeAg seroclearance has been accomplished, some aspects are yet unclear. We investigated the cumulative incidence of hepatocellula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hyun Woong, Lee, Jung Il, Kim, Saein, Kim, Sora, Chang, Hye Young, Lee, Kwan Sik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166314/ https://www.ncbi.nlm.nih.gov/pubmed/32305059 http://dx.doi.org/10.1186/s12876-020-01236-9

Ejemplares similares

Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance
por: Kim, Saein, et al.
Publicado: (2021)

Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B
por: Kim, Tae Hyung, et al.
Publicado: (2018)

Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile
por: Shiue, Sheng-Jie, et al.
Publicado: (2022)

Artificial Neural Network Accurately Predicts Hepatitis B Surface Antigen Seroclearance
por: Zheng, Ming-Hua, et al.
Publicado: (2014)

Using Machine Learning Algorithms to Predict Hepatitis B Surface Antigen Seroclearance
por: Tian, Xiaolu, et al.
Publicado: (2019)

Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues
por: Broquetas, Teresa, et al.
Publicado: (2017)

Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance
por: Park, Yewan, et al.
Publicado: (2021)

Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon
por: Wang, Peipei, et al.
Publicado: (2023)

Evaluation of HBsAg Seroclearance in Patients with Hepatitis B
por: Taşkın, Mehmet Can, et al.
Publicado: (2022)

Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection
por: Wu, Shuling, et al.
Publicado: (2022)

Clinical features of chronic hepatitis B patients with low hepatitis B surface antigen levels and determinants of hepatitis B surface antigen seroclearance
por: Taniguchi, Hideaki, et al.
Publicado: (2020)

Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy
por: Liang, Minfeng, et al.
Publicado: (2011)

Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance
por: Jang, Jeong Won, et al.
Publicado: (2021)

Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B
por: Hui, Ka-Yin, et al.
Publicado: (2023)

Spontaneous Hepatitis B Seroclearance upon Development of Hepatocellular Carcinoma
por: Naimimohasses, Sara, et al.
Publicado: (2017)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta‐analysis
por: Song, Aixin, et al.
Publicado: (2021)

On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B
por: Gao, Yu-Hua, et al.
Publicado: (2016)

Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses
por: Yeh, Ming-Lun, et al.
Publicado: (2011)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B
por: Yu, Ming-Whei, et al.
Publicado: (2022)

HBS Ag seroclearance and seroconversion time in Patients with chronic hepatitis B Infection
por: Masrour-Roudsari, Jila, et al.
Publicado: (2020)

Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer
por: Lou, Cheng, et al.
Publicado: (2018)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients
por: Ungtrakul, Teerapat, et al.
Publicado: (2017)

Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients
por: Cho, Eun Ju, et al.
Publicado: (2015)

Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report
por: Yeh, Chau-Ting, et al.
Publicado: (2018)

Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
por: Seto, Wai-Kay, et al.
Publicado: (2012)

The Role of Steatosis in HBsAg Seroclearance for Patients with Chronic Hepatitis B Infection: Fact or Fiction?
por: Fung, James, et al.
Publicado: (2012)

Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients
por: Cheng, Huei-Ru, et al.
Publicado: (2013)

Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss
por: Xue, Yan, et al.
Publicado: (2021)

Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B
por: Aung, Myo Nyein, et al.
Publicado: (2010)

Long-Term Hepatitis B Surface Antigen Profile and Seroclearance Following Antiviral Treatment: A Single-Center, Real-World Cohort Study
por: Huang, Chih-Wen, et al.
Publicado: (2023)

Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China
por: He, Yaozu, et al.
Publicado: (2023)

Management of chronic hepatitis B patients: Efficacy & limitation of nucleos(t)ide analogues
por: Inoue, Jun, et al.
Publicado: (2011)

The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis
por: Cholongitas, Evangelos, et al.
Publicado: (2015)

Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
por: Moreno-Cubero, Elia, et al.
Publicado: (2018)

Single-nucleotide polymorphism of rs7944135 (macrophage-expressed gene 1) is associated with hepatitis B surface antigen seroclearance in chronic hepatitis B infection: A cohort study
por: Irham, Lalu Muhammad, et al.
Publicado: (2019)

Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study
por: Park, Young Min, et al.
Publicado: (2016)

Seroclearance of Hbsag in Chronic Hepatitis B Virus Patients on Lamivudine Therapy: A 10 Year Experience
por: Sali, Shahnaz, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rpb8grn2c1afaq5mvr7ld1scna